RBC Bioscience Corporation
TWO: 6848.TWO0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Taipei Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mingwei Zhuo
- Employees
- 52
- Headquarters
- New Taipei City, Taiwan
- IPO year
- 2021
- Market cap
- NT$274.8M
- Website
- https://www.rbcbioscience.com
Loading 6848…
Loading profile data…Frequently asked questions about 6848
What does RBC Bioscience Corporation (6848.TWO) do?
RBC Bioscience Corporation researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. It offers molecular biomedical diagnostic and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissu...
Where does 6848.TWO trade?
RBC Bioscience Corporation (6848.TWO) trades on the Taipei Exchange.
What sector is 6848.TWO in?
RBC Bioscience Corporation (6848.TWO) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RBC Bioscience Corporation?
Mingwei Zhuo is the chief executive officer of RBC Bioscience Corporation (6848.TWO).
Where is RBC Bioscience Corporation headquartered?
RBC Bioscience Corporation is headquartered in Taiwan.
Does 6848.TWO pay a dividend?
Yes — RBC Bioscience Corporation (6848.TWO) paid a trailing twelve-month dividend of TWD 0.30 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did 6848.TWO go public?
RBC Bioscience Corporation (6848.TWO) completed its initial public offering in 2021.